We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization
Product News

Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization

Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization
Product News

Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Patents Granted in Key Territories as Novexatin® Moves Closer to Further Clinical Development and Commercialization"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NovaBiotics, has announced that it has further secured the global intellectual property position of its lead product, Novexatin® through recent patent grants in the US, EU and other territories worldwide. Novexatin® is a topical treatment for fungal nail infection and NovaBiotics’ recent patent grants protect the use of its core peptide technology in this and other related target indications.

The Company’s granted and pending IP not only protects the use of the core structure of Novexatin®, but of a related family of anti-infective peptides derived from the same technology platform. This is a critical milestone for the Company with key grants for its lead and follow-on products being secured a relatively early stage in their lifecycle.

NovaBiotics’ current antifungal product portfolio includes Novexatin® a phase 2b-ready clinical asset and Novamycin®, a candidate treatment for potentially life-threatening blood-stream and deep tissue yeast and mould infections (predominantly Candida).

In addition, NovaBiotics’ antibacterial peptide drug candidate, NP432 and novel mucolytic agent NM001 are now at the early proof of efficacy stage for the treatment of respiratory infections including multi-drug resistant forms and those associated with cystic fibrosis.

Dr Deborah O’Neil, Founder, commented: “Recent patent grants in key territories for our expanding product portfolio is an important step in NovaBiotics’ development, particularly as we bring our lead product Novexatin® closer to market. This undoubtedly adds significant further value for the interested parties with whom we are in ongoing discussions for Novexatin®.”

Advertisement